



ASCO 2026 TIP SHEET

Oral Presentations (9)

MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

Carl O. Landgren, MD, is a co-author.

Primary results of the phase 3 peak study of bezucastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST)

Jonathan Trent, MD, is a co-author.

Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by KIT mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.

Jonathan Trent, MD, is a co-author.

Correlation of ten-year survival with cell-free DNA methylation of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.

Michele Ceccarelli, MD, is a co-author.

Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).

Jonathan C. Trent is a co-author.

Intercepting Plasma Cell Disorders: From Smoldering Multiple Myeloma to Amyloid Light-Chain Amyloidosis

Rafat Abonour, MD, is a discussant.

Hematologic Malignancies-Plasma Cell Dyscrasia:
Panel Question and Answer

Rafat Abonour, MD, is a panelist.

Are We Breaking Barriers in Uveal Melanoma and Nonmelanoma Skin Cancers?

Jose Lutzky, MD, is the presenting author.

Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-Cell Therapy

Leonel F. Hernandez-Aya, MD, is a co-author.

Rapid Oral Presentations (7)

Association of NAB2-STAT6 distal fusion with risk level of metastatic disease and thoracic primary site.

Keerthana Sureshkumar, BS, is first and presenting author.

Career fulfillment and intent to leave among oncology physicians: A global survey.

Coral Olazagasti, MD, is first and presenting author.

MATRiX: A randomized phase II trial of tivantinib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.

Jose Lutzky, MD is a co-author.

A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI) -naive basal cell carcinoma of the head and neck.

Leonel Hernandez Aya is a co-author.

Efficacy of velutinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.

Jonathan C. Trent, MD, is a co-author.

Tegavivint, a downstream Wnt/B-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).

Lynn G. Feun is a co-author.

Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.

Leonel Hernandez Aya, MD, is a co-author.

Poster Presentations (55)

Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC.

Chinmay Jani, MD, is first and presenting author.

Lung cancer burden in AYAs: Global and U.S. trends.

Several Sylvester physicians are co-authors.

Tarlatamab in small cell lung cancer with brain metastases: A real-world experience.

Several Sylvester physicians are co-authors.

Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.

Raymond M. Vega, MD, MPH, is first and presenting author.

Racial disparities in endometrial cancer (EC) survival after molecular classification (MC).

Jill Roberts, MD, is first and presenting author.

[Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.](#)

Arjun Raj Rajanna, MSc, is first and presenting author.

[Association between survival outcomes in patients with multiple myeloma and treatment facility volume.](#)

Dickran G. Kazandjian, MD, is last and presenting author. Carl O. Landgren, MD, is first author.

[Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies \(ACT-GI\): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.](#)

Gerald A. Soff, MD, is first and presenting author.

[A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.](#)

Chinmay Jani, MBBS, is first and presenting author.

[Disaggregated lung cancer mortality trends in Asian American, Native Hawaiian, and Pacific Islander \(AANHPI\) patients by key sociodemographic features including sex, age, and smoking status.](#)

Diya Jayram, BA, is first and presenting author.

[Transposable elements and homotypic niches as drivers of immune dynamics and resistance in melanoma epigenetic-based immunotherapy.](#)

Teresa M. R. Noviello, PhD, is first and presenting author.

[Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.](#)

Mikkael Sekeres, MD, is a co-author.

[Navigating the post-covalent bruton tyrosine kinase inhibitor \(cTKi\) landscape in mantle cell lymphoma \(MCL\): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization \(HCRU\).](#)

Alvaro J. Alencar, MD, is first author.

[Temporal trends in pregnancy-associated cancer mortality in the United States: A national analysis 2018-2023.](#)

Diya Jayram, BA, is first and presenting author.

[Preparedness of internal medicine residents for oncologic emergencies and end-of-life discussions in a community training environment](#)

Daniel M. Lichtstein, MD, is senior author.

[Hematology-oncology bootcamp: Educational impact of an interactive, guideline-based "101" curriculum.](#)

Chinmay Jani, MBBS, is first and presenting author.

[Enabling blood-based mass spectrometry MRD detection in multiple myeloma without archived serum samples.](#)

Daniel J. Groso, BS, is first and presenting author.

[Predictors of EGFR-mutant primary lung adenocarcinoma.](#)

Lauren K. Groner, MD, is first author.

[Genomic characterization of conventional, dedifferentiated, and mesenchymal chondrosarcoma: A 550-patient multicenter analysis.](#)

Emanuela Palmerini, MD, and Jonathan C. Trent, MD, are co-authors, and Trent is last author.

[Distinct prognostic roles of IDH mutation and high-risk genomic alterations in patients with primary chondrosarcoma.](#)

Akshay Batra, MBBS, is first and presenting author.

[Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research \(FOSTER\) Consortium.](#)

Emanuela Palmerini, MD, PhD, is first and presenting author.

[Evaluating satisfactory testing versus transcript grade performance between childhood cancer survivors and healthy controls.](#)

Raymond M. Vega, MD, MPH, is first and presenting author.

[Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.](#)

Several Sylvester physicians are co-authors.

[Integrating personalized cDNA into clinical surveillance of soft tissue sarcoma: Performance, timing, and histologic insights.](#)

Amrit Paudel, MD, is first and presenting author and all co-authors are Sylvester-affiliated.

[Association of acute myeloid leukemia \(AML\) patient, disease, and molecular characteristics with a long-term \(LT\) response to olutasidenib.](#)

Justin M. Watts, MD, is first and presenting author.

[Interpretable machine learning to identify health system levers for survival outcomes of patients with prostate cancer.](#)

Brandon A. Mahal, MD, is a co-author.

[Machine learning approach to identify country-specific drivers of global cancer outcomes.](#)

Brandon A. Mahal, MD, is a co-author.

[Precision Promise \(PrP\): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer \(mPDAC\) in a multi-center trial.](#)

Jashodeep Datta, MD, is a co-author.

Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NC10208).

Nkiruka Ezenwajaku, MD, is a co-author.

A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti-CTLA-4 combined with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or with first-line durvalumab in advanced biliary tract cancer (BTC).

Lynn G. Feun, MD, is a co-author.

ETCTN 10302: A randomized phase I trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.

Carmen Calfa, MD, is a co-author.

Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.

Chukwuemeka Ikpeazu Sr., MD, is a co-author.

BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia-A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.

Agustin Pimentel, MD, is a co-author.

Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.

Leonel F. Hernandez-Aya, MD, is a co-author.

Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Carmen J. Calfa, MD, is a co-author.

Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.

Lawrence M. Negret, MD, is a co-author.

A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti-PD-1/PD-L1 antibody in participants with advanced non-small cell lung cancer * (NSCLC).

Estelamari Rodriguez, MD, is a co-author.

Efficacy and safety of pralsetinib in advanced or metastatic RET-altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.

Gilberto Lopes, MD, is a co-author.

A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [212pb]VMT01 melanocortin-1-receptor-targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.

Jose Lutzky, MD, is a co-author.

Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.

Eli Avisar, MD, and Jessica S. Crystal, MD, are co-authors.

Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial.

Jaime R. Merchan, MD, is a co-author.

Tumor methylation subtypes as a predictor of clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study.

Teresa M. R. Noviello, MD, and Michele Ceccarelli, MD, are co-authors.

Multi-modal AI foundation models approach for diagnosis of myelodysplastic syndromes across whole bone marrow aspirate and biopsy slides.

Mikkael A. Sekeres, MD, is a co-author.

Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).

Terrence J. Bradley, MD, is a co-author.

The hidden struggle? Mental health burden among oncology physicians globally.

Coral Olazagasti, MD, is first and presenting author.

Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).

Andrew Kowalski, MD, is a co-author.

Immune effector cell-associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel-treated patients with RRMM in CARTITUDE clinical studies.

Elizabeth Montgomery, MD, is a co-author.

Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.

Akshee Batra, MD, is a co-author.

Characterization of contemporary practice patterns in the management of IDH-mutant glioma: A multidisciplinary multi-institutional survey.

Marina Kushnirsky, MD, and Benjamin J. Rich, MD, are co-authors, and Rich is last author.

Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

Jonathan C. Trent, MD, is a co-author.

[A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.](#)

Carmen Calfa, MD, is a co-author.

[National real-world adoption of 5-fraction breast radiotherapy in the United States \(2020-2023\).](#)

Manan Patel, MD, is a co-author.

[Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.](#)

Priscila Barreto Coelho, MD, is a co-author.

[Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.](#)

Lawrence M. Negret, MD, is a co-author.

[Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed \(TCE\) relapsed/refractory multiple myeloma \(RRMM\): Updated matching-adjusted indirect comparison \(MAIC\) with longer follow-up.](#)

James E. Hoffman, MD, is a co-author.

Special Sessions (2)

[The Art of Getting Published in the Art of Oncology](#)

JCO Associate Editor, Mikkael Sekeres, MD, leads a panel discussion.

[Navigating a Successful Career in Academic Oncology: Strategies Throughout Your Many Chapters](#)

Gilberto Lopes, MD, presents an “International Medical Graduate Perspective” in this education session.

###

MEDIA CONTACT:

Sandy Van

[**sandy.van@miami.edu**](mailto:sandy.van@miami.edu)